Published in Eur Heart J on October 04, 2006
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA (2008) 2.47
Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv (2008) 1.84
Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv (2008) 1.49
Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? Catheter Cardiovasc Interv (2008) 1.39
Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire? Eur Heart J (2006) 1.39
Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2008) 1.18
Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. Int J Cardiovasc Imaging (2011) 1.17
Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study. Evid Based Complement Alternat Med (2013) 0.92
New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol (2013) 0.87
Prevention of restenosis: is angioplasty the answer? Heart (2007) 0.87
Assessment of optimum stent deployment by stent boost imaging: comparison with intravascular ultrasound. Heart Vessels (2011) 0.86
Macro- and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expression. J R Soc Interface (2014) 0.86
Comparison of three age groups regarding safety and efficacy of drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol (2011) 0.85
Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.84
Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv (2015) 0.83
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up. Clin Res Cardiol (2007) 0.83
The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Can J Cardiol (2007) 0.83
Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry). Am J Cardiol (2011) 0.83
Late outcomes following percutaneous coronary interventions: results from a large, observational registry. Can J Cardiol (2010) 0.82
Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video). BMJ Case Rep (2013) 0.82
Impact of the introduction of drug eluting stents on clinical outcomes in patients undergoing percutaneous and surgical coronary artery revascularisation procedures in Western Australia. BMC Cardiovasc Disord (2013) 0.81
Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting. Vasc Health Risk Manag (2011) 0.80
CT virtual endoscopy and 3D stereoscopic visualisation in the evaluation of coronary stenting. Biomed Imaging Interv J (2009) 0.80
Trends in hospital discharges, management and in-hospital mortality from acute myocardial infarction in Switzerland between 1998 and 2008. BMC Public Health (2013) 0.80
Drug-eluting stents with biodegradable polymer for the treatment of patients with diabetes mellitus: clinical outcome at 2 years in a large population of patients. Med Devices (Auckl) (2015) 0.79
Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol (2010) 0.79
Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocol. BMJ Open (2014) 0.78
Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry. Heart Vessels (2011) 0.77
Stent thrombosis: antiplatelets alone won't do the job. BMJ (2007) 0.76
Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis. BMC Cardiovasc Disord (2012) 0.76
Interventional cardiology and the medical devices industry: is there a conflict of interest? Heart (2007) 0.76
Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. Sci Rep (2015) 0.76
The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view. Med Devices (Auckl) (2014) 0.76
Drug-eluting coronary stents - focus on improved patient outcomes. Patient Relat Outcome Meas (2011) 0.76
Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography. Int J Cardiovasc Imaging (2013) 0.76
Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study. Int J Cardiovasc Imaging (2012) 0.75
Patient with recent coronary artery stent requiring major non cardiac surgery. Indian J Anaesth (2009) 0.75
Preliminary Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary Artery Disease: Results of the MANIPAL-FLEX Study. Scientifica (Cairo) (2016) 0.75
Review: drug-eluting stents for coronary artery disease do not reduce mortality more than bare-metal stents. ACP J Club (2007) 0.75
Advances in drug eluting stents - focus on the Endeavor(®) zotarolimus stent. Med Devices (Auckl) (2008) 0.75
Lack of efficacy and cost-effectiveness of drug-eluting stents. Eur Heart J (2006) 0.75
Surface Modification of Biodegradable Polymers towards Better Biocompatibility and Lower Thrombogenicity. PLoS One (2015) 0.75
Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison. Tex Heart Inst J (2011) 0.75
First human trial of KW39 slotted-tube stents: for percutaneous coronary intervention. Tex Heart Inst J (2011) 0.75
Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiol Sin (2017) 0.75
Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus. Glycoconj J (2008) 0.75
Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. Eur J Clin Pharmacol (2007) 0.75
In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis. J Mater Sci Mater Med (2011) 0.75
Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43
Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med (2015) 6.06
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA (2013) 4.33
Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med (2006) 4.19
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54
Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med (2011) 2.97
Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 2.95
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol (2011) 2.72
Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (2012) 2.69
Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol (2011) 2.69
Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med (2005) 2.55
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev (2012) 2.31
Systematic reviewers neglect bias that results from trials stopped early for benefit. J Clin Epidemiol (2007) 2.20
Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol (2008) 2.18
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health (2013) 2.12
Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ (2007) 2.07
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol (2012) 2.00
Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med (2011) 1.87
Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ (2012) 1.85
Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev (2011) 1.82
Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis. Crit Care Med (2010) 1.78
Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis (2012) 1.67
The Clinical Effectiveness of Pneumococcal Conjugate Vaccines. Dtsch Arztebl Int (2016) 1.49
Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med (2015) 1.48
Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One (2012) 1.48
Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One (2013) 1.40
Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev (2016) 1.38
LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact. Trials (2009) 1.32
The pylorus: take it or leave it? Systematic review and meta-analysis of pylorus-preserving versus standard whipple pancreaticoduodenectomy for pancreatic or periampullary cancer. Ann Surg Oncol (2007) 1.24
Meta-analyses: what they can and cannot do. Swiss Med Wkly (2012) 1.23
Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol (2012) 1.18
The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ (2011) 1.17
The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging (2011) 1.12
Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study). BMC Med Res Methodol (2012) 1.10
Completion and Publication Rates of Randomized Controlled Trials in Surgery: An Empirical Study. Ann Surg (2015) 1.06
Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ (2014) 1.03
Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta-analysis of randomized controlled trials. J Crit Care (2009) 1.03
Detecting, quantifying and adjusting for publication bias in meta-analyses: protocol of a systematic review on methods. Syst Rev (2013) 1.00
Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it? Stat Methods Med Res (2011) 0.98
Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA (2013) 0.97
Defining publication bias: protocol for a systematic review of highly cited articles and proposal for a new framework. Syst Rev (2013) 0.96
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J (2011) 0.95
Blood pressure targets for vasopressor therapy: a systematic review. Shock (2015) 0.89
A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol. Syst Rev (2013) 0.87
Statins for acute coronary syndrome. Cochrane Database Syst Rev (2014) 0.87
Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. Value Health (2011) 0.87
Vasopressor administration and sepsis: a survey of Canadian intensivists. J Crit Care (2011) 0.87
A protocol for a systematic review on the impact of unpublished studies and studies published in the gray literature in meta-analyses. Syst Rev (2013) 0.87
Statins for acute coronary syndrome. Cochrane Database Syst Rev (2011) 0.86
Problems of stopping trials early. BMJ (2012) 0.86
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev (2015) 0.86
Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis. J Clin Epidemiol (2013) 0.84
Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials (2015) 0.84
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med (2013) 0.83
Premature Discontinuation of Randomized Trials in Critical and Emergency Care: A Retrospective Cohort Study. Crit Care Med (2016) 0.80
Towards tailored radiopeptide therapy. Eur J Nucl Med Mol Imaging (2015) 0.79
Short versus conventional term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease - the "REDUCE" trial. Swiss Med Wkly (2010) 0.78
Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design. Trials (2013) 0.78
Substitutes of structural and non-structural autologous bone grafts in hindfoot arthrodeses and osteotomies: a systematic review. BMC Musculoskelet Disord (2013) 0.78
Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation--protocol of the ICEM study. Syst Rev (2014) 0.77
Methodological survey of designed uneven randomization trials (DU-RANDOM): a protocol. Trials (2014) 0.77
Statins: pleiotropic, but less than previously thought. Eur Heart J (2012) 0.76
Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev (2016) 0.76
Hemodynamic performance of stentless versus stented valves: a systematic review and meta-analysis. J Card Surg (2008) 0.75
Copeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study. Clin Chem Lab Med (2016) 0.75
Response by authors. Evid Based Child Health (2013) 0.75
Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. Syst Rev (2014) 0.75
Interactive booklet reduces antibiotic prescribing for respiratory tract infections in children, but not parent satisfaction. Evid Based Nurs (2010) 0.75
A systematic review of nonabsorbable, absorbable, and steroid-impregnated spacers following endoscopic sinus surgery. Int Forum Allergy Rhinol (2013) 0.75
Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial. Trials (2014) 0.75
Choice of data extraction tools for systematic reviews depends on resources and review complexity. J Clin Epidemiol (2009) 0.75
In Reply. Dtsch Arztebl Int (2016) 0.75
Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev (2017) 0.75
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev (2017) 0.75
[Instructions for aggregated evidence: Systematic reviews and meta-analyses (part 1)]. Med Monatsschr Pharm (2015) 0.75
Reply: Somatostatin Receptor-Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma. J Nucl Med (2016) 0.75
[Instructions for aggregated evidence: About reviews, systematic reviews and meta-analyses (part 2)]. Med Monatsschr Pharm (2015) 0.75
[Is procalcitonin determination for control of antibiotic therapy in acute respiratory infections of value?]. Praxis (Bern 1994) (2013) 0.75
[Four numbers and a bit more basic knowledge of mathematics]. Med Monatsschr Pharm (2015) 0.75